Lightstone Ventures has appointed Susan M. Molineaux, Ph.D. as Scientific Advisor.
In this role, she will assist the LSV biotechnology team with deal sourcing and due diligence.
Dr. Molineaux also continues to serve as the President, Chief Executive Officer (CEO) and as a Member of the Board of Directors of Calithera Biosciences (NASDAQ: CALA), and as a Member of the Boards of Directors of Geron Corporation (NASDAQ: GERN) and Theravance Biopharma, Inc. (NASDAQ: TBPH).
Prior to co-founding Calithera in 2010, she co-founded Proteolix and served at various times as either Chief Scientific Officer or CEO from 2003 until the company was acquired by Onyx Pharmaceuticals in November 2009 for up to $851m. Under Dr. Molineaux’s leadership, Proteolix developed the proteasome inhibitor carfilzomib (Kyprolis®), which was approved in 2012 for the treatment of advanced multiple myeloma. From 1994 to 2003, she held scientific leadership positions at Rigel Pharmaceuticals, Praelux, and Praecis Pharmaceuticals.
Dr. Molineaux began her career at Merck & Co., Inc., where she was a scientist in the Immunology group.
Led by General Partner Jean M. George, Lightstone Ventures (LSV) invests in early-stage medical device and biopharmaceutical companies .
The biopharmaceutical portfolio currently includes Nimbus Therapeutics, Alexo Therapeutics, Ra Pharmaceuticals, Flex Pharma, and Catabasis Pharmaceuticals. In May 2016, Gilead Sciences acquired Nimbus Apollo, a wholly-owned subsidiary of Nimbus Therapeutics, in a deal valued up to $1.2 billion. LSV has also invested in Claret Medical, Earlens Corporation; Cala Heath, and Foundry Innovation & Research 1 in the medical device sector.